Free tool
FAERS Monitor: Lexette
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210566 or its brand name (Lexette, Halobetasol Propionate). Reports on generic versions are filed under their own applications.
Reports
918
Serious
259
28% of reports
Hospitalization
101
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective198
- psoriasis135
- pruritus91
- product use in unapproved indication73
- rash65
- dry skin50
- arthralgia49
- dermatitis atopic49
- skin exfoliation45
- pain44
- product dose omission issue38
- therapeutic product effect incomplete38
- fatigue35
- off label use34
- injection site pain33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 2 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 9 |
| 2013 | 14 |
| 2014 | 11 |
| 2015 | 26 |
| 2016 | 36 |
| 2017 | 27 |
| 2018 | 31 |
| 2019 | 46 |
| 2020 | 63 |
| 2021 | 72 |
| 2022 | 140 |
| 2023 | 233 |
| 2024 | 74 |
| 2025 | 67 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,241 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 135 | 23.7 | 20.3 | 2,928 |
| dermatitis atopicSignal | 49 | 21.3 | 16.2 | 930 |
| therapeutic product effect incompleteSignal | 38 | 12.2 | 9.0 | 382 |
| skin exfoliationSignal | 45 | 12.2 | 9.2 | 454 |
| dry skinSignal | 50 | 8.6 | 6.6 | 329 |
| product use in unapproved indicationSignal | 73 | 6.8 | 5.4 | 356 |
| pruritusSignal | 91 | 5.4 | 4.5 | 330 |
| drug ineffectiveSignal | 198 | 3.4 | 3.0 | 363 |
| rashSignal | 65 | 3.4 | 2.7 | 111 |
| product dose omission issueSignal | 38 | 3.0 | 2.2 | 48 |
| arthralgiaSignal | 49 | 2.7 | 2.1 | 52 |
| injection site painSignal | 33 | 2.5 | 1.8 | 28 |
| pain | 44 | 1.6 | 1.2 | 11 |
| fatigue | 35 | 1.0 | 0.7 | 0 |
| off label use | 34 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.